Business
Agios reports results from late-stage study of its thalassemia treatment (NASDAQ:AGIO)
RBC) inside a Vein” data-id=”1217640102″ data-type=”getty-image” width=”5600px” height=”3500px” srcset=”https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1217640102/image_1217640102.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1217640102/image_1217640102.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1217640102/image_1217640102.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1217640102/image_1217640102.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1217640102/image_1217640102.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1217640102/image_1217640102.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1217640102/image_1217640102.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1217640102/image_1217640102.jpg?io=getty-c-w240 240w” sizes=”(max-width: 768px) calc(100vw – 36px), (max-width: 1024px) calc(100vw – 132px), (max-width: 1200px) calc(66.6vw – 72px), 600px”> fpm/iStock via Getty Images
- Agios Pharmaceuticals (NASDAQ:AGIO) presented positive results from late-stage study investigating mitapivat, an oral, small molecule PK activator, in adults with transfusion-dependent alpha- or beta-thalassemia.
- Stock is down 7% premarket.
- Mitapivat demonstrated a statistically significant reduction in transfusion burden vs placebo
Source link
